ARCTArcturus Therapeutics Holdings Inc.

$217M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$39M-10.5% YoY

Gross Profit

$39M100.0% margin

Operating Income

-$11M-27.7% margin

Net Income

-$7M-17.8% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

-15.6%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$371M

Total Liabilities

$109M

Stockholders' Equity

$262M

Cash & Equivalents

$237M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$39M	$43M	-10.5%
Gross Profit	$39M	$43M	-10.5%
Operating Income	-$11M	-$19M	+44.4%
Net Income	-$7M	-$16M	+57.4%

Revenue Segments

Collaboration Revenue

$39M93%

Grant

$3M7%

ARCT Q3 2024 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena